Related Experiment Video
Updated: Jan 15, 2026

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
Published on: May 31, 2024
Research Communication: Comparative Effectiveness of Ustekinumab and Vedolizumab in the Management of Chronic
Saqr Alsakarneh1, June Tome1, Francis A Farraye2
1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Introduction:
Chronic pouchitis is a major therapeutic challenge in patients with ulcerative colitis following ileal pouch-anal anastomosis.
Methods:
We conducted a real-world, propensity-matched cohort study of 856 patients from a healthcare database to compare ustekinumab and vedolizumab.
Results:
Ustekinumab was associated with significantly lower relapse rates (aHR = 0.69; p < 0.001), longer time to relapse, reduced hospitalisation and decreased need for steroids or antibiotics. No differences were observed in surgery rates or therapy switching.
Conclusion:
Our findings suggest that ustekinumab may offer advantages over vedolizumab in the management of chronic pouchitis.
More Related Videos
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...

